HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. Under the ongoi ...

Weinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $5 billion in exits across healthcare, biotechnology, and nutrition.Weinstein’s ownership is expected to increase to approximately 30% on an issued and outstanding basis, reflecting his conviction in Pluri’s asset base, its valuation potential, and its long term strategy. HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (N ...

Core Insights - Pluri Inc. has received multiple awards recognizing its innovation and leadership in biotechnology, particularly in cell-based solutions for agriculture and sustainable food systems [1][2][4] Group 1: Awards and Recognitions - Pluri was named Overall BioAgriculture Company of the Year by the Biotech Breakthrough Awards, highlighting its advancements in applying cell therapy to agriculture [2] - The company won the 2024 Egalitarian Employment Award in the Large Company category from Israel's Ministry of Labor, Social Affairs and Social Services, with a government grant of 40,000 NIS expected alongside the award [3] - Pluri's subsidiaries, Coffeesai Ltd. and Kokomodo Ltd., received significant industry awards for their innovative approaches in sustainable food production and climate-resilient agriculture [7] Group 2: Company Position and Strategy - Pluri is positioned as a leader in biotechnology, developing patented technologies that have the potential to transform various industries, including regenerative medicine and agtech [4] - The company's proprietary 3D cell expansion platform enables scalable production of cell-based products, facilitating partnerships in multiple sectors [4][5] - The CEO emphasized the strength and versatility of Pluri's platform, reflecting market confidence in its strategy to apply cell-based innovation across industries [5]

Financial Performance - Revenues for the three-month period ended September 30, 2025, were $316,000, a decrease of 3% compared to $326,000 for the same period in 2024[87]. - Net loss for the three-month period ended September 30, 2025, was $6,132,000, compared to a net loss of $6,036,000 for the same period in 2024, primarily due to increased R&D and administrative expenses[93]. - Loss per share for the three-month period ended September 30, 2025, was $0.65, a decrease from $1.08 loss per share in the same period of 2024, attributed to an increase in the weighted average number of shares outstanding[94]. Expenses - Cost of revenues increased by 59% from $126,000 in the three-month period ended September 30, 2024, to $201,000 in the same period of 2025, primarily due to higher personnel costs[88]. - R&D expenses, net, rose by 36% from $2,889,000 for the three-month period ended September 30, 2024, to $3,931,000 in 2025, attributed to increased salaries and new employee additions following the acquisition of Kokomodo[89]. - General and administrative expenses increased by 1% from $2,509,000 in the three-month period ended September 30, 2024, to $2,534,000 in 2025, mainly due to higher share-based compensation expenses[90]. Business Developments - The company launched a new business division, PluriCDMO™, in January 2024, offering cell therapy manufacturing services and generating revenues from several client agreements[77]. - The company completed the acquisition of approximately 79% of Kokomodo, an innovative agfood startup, on April 28, 2025, to enhance its capabilities in sustainable cacao production[80]. - In June 2024, Ever After Foods raised $10 million in a funding round to support its B2B technology platform for cultivated meat, with Pluri Biotech investing $1.25 million[83]. Strategic Initiatives - The company is actively pursuing collaborations in AgTech, including partnerships to enhance bio stimulant delivery and develop cell-cultured coffee and cacao[78][79]. - The company aims to expand its technology applications across various industries, including regenerative medicine, food technology, and agriculture technology[70]. - The company is focused on developing placenta-based cell therapy product candidates for inflammatory and hematologic conditions, as well as launching a novel immunotherapy platform utilizing MAIT cells[72][75]. Financial Position - Total current assets as of September 30, 2025, were $16,921,000, while total current liabilities were $32,160,000, resulting in a working capital deficit of $15,239,000[96]. - Cash used in operating activities increased to $5,428,000 during the three months ended September 30, 2025, compared to $4,064,000 in the same period of 2024[98]. - Cash provided by investing activities was $3,850,000 for the three months ended September 30, 2025, compared to $585,000 in the same period of 2024[99]. - As of September 30, 2025, cash and cash equivalents totaled $4,687,000, an increase from $3,563,000 as of September 30, 2024[97]. Liquidity and Going Concern - The company has accumulated a deficit of $448,905,000 since inception and does not anticipate generating significant revenues from product sales in the next twelve months[117]. - The company is addressing liquidity issues by implementing initiatives to continue operations, with cash balances totaling $16,393,000 as of September 30, 2025[118]. - Management estimates insufficient resources to meet operating obligations for at least twelve months from the issuance date of the financial statements, raising substantial doubt about the company's ability to continue as a going concern[120]. - The company received a total of $2.3 million in funding under the NIAID contract before its termination on April 15, 2025[109].

Core Insights - Pluri Inc. has launched a wholly-owned subsidiary, Cellav Health and Aesthetics Ltd., focusing on regenerative solutions using its proprietary 3D cell expansion platform [1][6] - Cellav has secured a commercial collaboration with Miss Universe Skincare to co-develop a new line of advanced, cell-based skincare products [1][2] - The first product from this collaboration is expected to launch in the first half of 2026, leveraging Miss Universe Skincare's global distribution platform [2][6] Company Overview - Cellav aims to transform cutting-edge cell science into impactful solutions for health and aesthetics, bridging science with real-world results [5][7] - The subsidiary will operate in three core areas: developing premium cell-derived ingredients, offering professional-use and consumer-ready products, and providing a flexible technology platform for partners [7] - Cellav's offerings are backed by over two decades of Pluri's expertise in pharmaceutical-grade development [7] Market Potential - The beauty market, where Cellav is expanding, is projected to reach $194.05 billion by 2032, indicating significant growth opportunities [6] - The collaboration with Miss Universe Skincare is seen as a strategic move to tap into high-growth, revenue-generating markets [2][4] Leadership and Vision - Cellav is led by CEO Katty Dowery, who has extensive experience in cell-based technologies and regenerative medicine [3][4] - The company emphasizes scientific integrity and high-quality standards, aiming to make regenerative science accessible and impactful in the beauty industry [4][5]

Core Insights - Pluri, Inc. has entered significant international collaborations through its foodtech and agtech subsidiaries, marking a major advancement in its mission to transform food and agriculture production using advanced 3D cell-expansion technology [1][2][3] Company Overview - Pluri operates three subsidiaries: Ever After Foods, Kokomodo, and Coffeesai, which have signed collaboration agreements with global leaders in food and agtech across Asia, Europe, and the U.S. This expansion indicates increasing commercial viability and global demand for sustainable, cell-based innovations [2][4] - The collaborations are anchored by a minimum-viable-product (MVP) funded by leading global players, showcasing substantial commitment and trust in the innovative potential of these partnerships [4] Subsidiary Developments - Ever After Foods is advancing scale-up validation and pre-commercial trials with food companies, focusing on turning pipeline projects into pilot results while maintaining a capital-efficient business model [5] - Kokomodo has signed strategic agreements with a European food innovation firm and a U.S.-based multinational, aiming to enhance its research, development, and manufacturing capabilities in the cacao industry [5] - Coffeesai has entered a collaboration with a major East Asian food and beverage conglomerate to accelerate eco-friendly coffee production through cell-based cultivation, minimizing the environmental impact of traditional farming [5] Market Context - The momentum of Pluri's initiatives comes at a time of rising demand for sustainable solutions in agriculture, driven by challenges such as climate change, dwindling natural resources, and a growing global population [3][4] - Pluri's proprietary 3D cell expansion platform enables rapid scaling of next-generation food and agriculture solutions with significantly reduced environmental footprints, addressing global challenges in sustainable food production and climate resilience [6]

Core Insights - Pluri Inc. is recognized as a promising long-term penny stock with significant upside potential, particularly following its recent collaboration with a Mexican public body to advance cell-based coffee manufacturing [1][3]. Group 1: Collaboration and Innovation - Pluri's subsidiary, Coffeesai Ltd., has entered into a collaboration agreement with Instituto del Café de Chiapas/INCAFECH to promote cell-based coffee production in Chiapas, Mexico, which is known as the leading coffee-growing region in the country [1][2]. - The partnership aims to establish Chiapas as a hub for innovation in coffee manufacturing, leveraging state support to enhance the commercialization of cell-based coffee products [1][2]. Group 2: Business Model and Revenue Generation - Coffeesai utilizes Pluri's proprietary 3D cell expansion platform and two decades of expertise to develop sustainable cell-based coffee products, outlining a multi-phase, capital-light roadmap to mitigate commercialization risks [2][3]. - The collaboration is expected to create shareholder value through potential non-dilutive revenues from licensing and technology transfer, as well as recurring revenue streams from royalty-bearing models and joint ventures [3]. Group 3: Company Overview - Pluri Inc. is a biotechnology company focused on researching, developing, and manufacturing cell-based products and related technologies across various industries [4].

Core Insights - Pluri Inc. has announced a collaboration with Instituto del Café de Chiapas to advance cell-based coffee manufacturing in Mexico, leveraging its subsidiary Coffeesai's technology [1][2][4] Group 1: Collaboration and Strategy - The collaboration aims to establish Chiapas as a hub for cell-based coffee innovation, combining biotechnology with local coffee traditions [2][4] - The partnership is structured around a three-phase roadmap to de-risk commercialization, starting with cell line development and moving towards pilot-scale biofarming and commercial-scale manufacturing [5][6] Group 2: Market Potential and Financial Outlook - The global coffee market exceeded $250 billion in 2024 and is projected to surpass $350 billion by 2030, indicating a significant opportunity for scalable production [5] - The collaboration is expected to create a revenue-generating model aligned with shareholder interests while transforming the future of coffee production [4][5] Group 3: Technological Innovation - Coffeesai will utilize Pluri's proprietary 3D cell expansion platform to develop sustainable coffee solutions that are resilient to climate change and market volatility [5][8] - The innovative process aims to eliminate the negative environmental impacts associated with traditional coffee farming, ensuring consistent quality and high yields [8]

Acquisition and Partnerships - The company completed the acquisition of approximately 79% of Kokomodo, an innovative agfood startup focused on sustainable cacao production using cellular agriculture technology[27] - The company holds approximately 69% of Ever After Foods, which focuses on scalable production technologies for cultivated meat[31] - Ever After Foods entered a strategic collaboration with Bühler Group to advance scalable cultivated meat production systems, aiming to reduce costs and support global food security[55] - The company has established strategic partnerships, including with Tnuva and ICL Group, to enhance its product development and market reach[170] Funding and Financial Agreements - In June 2024, the company raised $10 million through a private placement offering for Ever After Foods, with the company investing $1.25 million, aiming to support its B2B technology platform for cultivated meat[30] - The company executed a finance agreement with EIB for non-dilutive funding of up to €50 million, intended to support R&D in the EU[71] - The company received a loan of up to €50 million from the EIB, with the first tranche of €20 million received in June 2021, due for repayment on June 1, 2026, with accrued interest of approximately €3.27 million as of June 30, 2025[133] - A €7.5 million non-dilutive grant was awarded to the PROTO project from the EU's Horizon program for treating knee osteoarthritis[78] Product Development and Technology - The company launched a novel allogenic immunotherapy platform utilizing MAIT cells in May 2024, designed to address solid tumors, which are currently a critical area in medicine[20] - The company established a new business division, PluriCDMO™, in January 2024, offering cell therapy manufacturing services and generating revenues from several client agreements[22] - The company is developing cell-cultured coffee through its subsidiary Coffeesai, addressing challenges in the traditional coffee industry and demonstrating a proof-of-concept beverage[25][26] - The company has a unique 3D cell expansion platform that enables high-quality cell production at commercially relevant volumes, applicable across various sectors including regenerative medicine and AgTech[34][36] - The company launched a cell-based coffee business, PluriAgTech, in January 2024 to meet the demand for sustainable coffee production[57] Clinical Trials and Regulatory Compliance - PLX-PAD and PLX-R18 products have been tested in clinical studies for various indications, with PLX-PAD being developed for knee osteoarthritis as part of an international collaboration[41][42] - The company has submitted an Investigational New Drug (IND) Application, which must be effective before clinical testing in humans can begin[96] - The in-house clinical manufacturing facility has been operational since February 2013, approved for producing PLX-PAD and PLX-R18 for clinical use[86] - The facility continues to comply with GMP standards and has been inspected by a European Union Qualified Person in December 2024[87] Intellectual Property and Patents - The company holds 193 issued patents and approximately 55 pending patent applications across multiple jurisdictions, including the U.S., Europe, and Asia[61] - A new patent approval from the Israel Patent Office in March 2024 represents a breakthrough in 3D bioreactor technology for efficient plant cell cultivation[58] - The patent portfolio includes claims for proprietary 3D cell expansion methods for both adherent and suspension cells, covering various therapeutic applications[63] - The expiration dates of the patents range from 2027 to 2044, with potential extensions based on regulatory delays[67] - The company emphasizes the importance of protecting its intellectual property through patents and confidentiality agreements[60] Financial Performance and Risks - The company has a history of losses and has not generated significant revenues to date, expecting future losses and potential difficulties in raising additional capital[119] - The independent registered public accounting firm has included an explanatory paragraph regarding the company's ability to continue as a going concern in its audited financial statements[119] - As of June 30, 2025, the company's cash balances totaled $21,914,000, which is insufficient to meet operating obligations for at least twelve months[124] - The company anticipates needing to raise significant additional capital in the future to support research, development, and manufacturing of cell-based products[126] - The company faces risks related to the development and commercialization of its products, which are currently in the development stage and require regulatory approvals[129] Market Competition and Challenges - The company is facing intense competition in the regenerative medicine field, with 2,096 cell-based therapies in development globally, including 820 gene-modified and cellular immunotherapies[106] - The company operates in a competitive landscape for cultivated meat, with a unique proprietary technology that allows for lower-cost and larger-scale production[109] - The cellular therapeutics industry is highly competitive, with many companies targeting the same diseases, which could render the company's products obsolete if it fails to keep pace with technological advancements[199] - The trend towards consolidation in the pharmaceutical and biotechnology industries may lead to increased competition and fewer collaboration opportunities for the company[198] Operational and Compliance Risks - The company is dependent on third-party suppliers for raw materials necessary for manufacturing, which poses risks to its ability to deliver products on time[204] - Cybersecurity incidents and technology disruptions could adversely affect the company's operations and reputation, particularly regarding compliance with privacy laws[210] - The company is exposed to fluctuations in currency exchange rates due to a significant portion of its business being conducted outside the United States[124] - The company has implemented a hedging strategy using options and forward contracts to mitigate currency exchange risks[195] Future Outlook and Strategic Initiatives - Ever After Foods has a limited operating history in the cultivated meat sector, making its future prospects difficult to predict[152] - The company is focused on developing industrial-scale cultivated meat technologies and processes, which are crucial for its market success[152] - The success of Ever After Foods' cultivated meat products will depend on consumer preferences, which are difficult to predict and may change[156] - The company is working with regulatory consultants to determine if its cultivated plant-based products can be classified as "Generally Recognized as Safe" (GRAS) under FDA regulations[166]

Core Insights - Pluri Inc. aims to lead a global biotech revolution in healthcare, food, and agriculture through its innovative cell expansion platform, which allows for the production of pharmaceuticals, food products, and agricultural goods to address multi-billion dollar markets [1][10] Business Developments - The company anticipates a significant turning point in the upcoming fiscal year by unlocking the potential of its cell expansion technology, particularly in the cocoa and coffee industries, which are facing shortages due to climate change and rising demand [2][9] - Pluri has strengthened its position in the cultivated cacao space by partnering with an Israeli AgFoodTech company that is developing cell-based cacao technology, addressing challenges in the global cacao industry [3][10] - The company has secured additional investment from a new strategic partner with expertise in healthcare, enhancing its financial position and ability to expand into key geographies [4][10] Financial Performance - In the first nine months of fiscal year 2025, Pluri recorded a fourfold increase in revenue, rising from $230,000 in the same period of fiscal year 2024 to $938,000, driven by its CDMO and AgTech businesses [7][8] - The company is advancing new food tech partnerships and licensing opportunities, contributing to its revenue growth [8][10] Strategic Initiatives - Pluri holds a 69% stake in Ever After Foods Ltd., which utilizes its cell expansion technology for cultivated meat production, with significant funding rounds supporting this initiative [5][10] - The company is actively discussing commercial implementation opportunities with leading players in the cocoa and coffee industries, including potential out-licensing to strategic partners [9][10] Research and Development - Pluri has received $2.2 million in funding from the U.S. National Institutes of Health and the Department of Defense for the development of PLX-R18 for treating Acute Radiation Syndrome, although this funding has been discontinued due to federal budget cuts [6][10]